Xiwei Feng
Key Laboratory Of Basic And Translational Research On Immune Mediated Skin Diseases
Nanjing, China
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Efficacy of the Bispecific Anti-BAFF/IL-21 Antibody CZ105 Bis2 in Models of Systemic Lupus Erythematosus.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: March 21, 2025
Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Autoimmune Diseases.
Journal: Clinical reviews in allergy & immunology
Published: February 04, 2025
T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain as a promising immune checkpoint target for the treatment of SLE.
Journal: Lupus
Published: January 30, 2024
Blockade of OX40/OX40L signaling using anti-OX40L alleviates murine lupus nephritis.
Journal: European journal of immunology
Published: November 24, 2023
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus.
Journal: Signal transduction and targeted therapy
Published: November 24, 2023
CYSLTR1 antagonist inhibits Th17 cell differentiation by regulating the NF-κB signaling for the treatment of psoriasis.
Journal: International journal of biological sciences
Published: November 23, 2023
TIGIT-Fc fusion protein alleviates murine lupus nephritis through the regulation of SPI-B-PAX5-XBP1 axis-mediated B-cell differentiation.
Journal: Journal of autoimmunity
Published: April 30, 2023
TIGIT: An emerging immune checkpoint target for immunotherapy in autoimmune disease and cancer.
Journal: International immunopharmacology
Published: April 02, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026